COOPERATIVE-PFA: A Three-Arm Randomized Controlled Trial
Circulation · 22.07.2025 · 152 (3) · 150-159
DOI: 10.1161/circulationaha.125.074427 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 22.07.2025. Verfasst von Veronika Sochorová und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesia and Intensive Care Medicine, Third Faculty of Medicine, Charles University Prague and University Hospital Kralovske Vinohrad…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Propofol, Catheter Ablation, Ketamine. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Research of Metabolic and Cardiovascular Diseases.
Abstract (Originalsprache)
BACKGROUND: Deep analgosedation (DAS) or general anesthesia is mandatory for pulsed-field ablation of atrial fibrillation. In contrast to DAS, general anesthesia (conventional or total intravenous anesthesia [TIVA]) requires airway management. To find the optimal sedation regimen, this study compared ketamine-remimazolam DAS and propofol-opioid TIVA with propofol-opioid DAS, focusing on sedation-related adverse events. METHODS: Patients indicated for atrial fibrillation catheter ablation were randomly assigned at a 1:1:1 ratio to: (1) DAS using intermittent propofol-opioid boluses (arm P), (2) continuous remimazolam-ketamine DAS (arm R), or (3) continuous propofol-opioid TIVA with secured airway (arm TIVA). Catheter ablation was performed using the FARAPULSE system (Boston Scientific, MA). The major exclusion criterion was obstructive sleep apnea syndrome. The primary end point was defined as a composite of hypoxemia, hypotensive, or hypertensive events requiring intervention or leading to procedure discontinuation. Secondary end points included hemodynamic instability events, procedure time, serious adverse events, and patient satisfaction. RESULTS: One-hundred twenty-seven patients (mean age 62.9±10.3 years, 35.1% women, 47.2% with paroxysmal atrial fibrillation) were enrolled and randomized to the P (n=42), R (n=43), or TIVA (n=42) arms. The primary end point occurred in 85.7% of P patients, 27.9% of R patients, and 66.7% of TIVA patients ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesia and Intensive Care Medicine, Third Faculty of Medicine, Charles University Prague and University Hospital Kralovske Vinohrady, Prague, Czech Republic (V.S., V.K., F.D., P.W.).
- Cardiocenter, Third Faculty of Medicine, Charles University Prague and University Hospital Kralovske Vinohrady, Prague, Czech Republic (P.O., D.H., L.P., J.K., L.Z., V.F., J.H., J.V., M.H.).
ORCID-Profile: Pavel Osmančík, František Duška, Dalibor Heřman, Petr Waldauf, Věra Filipcová, Jana Veselá, Marek Hozman
Förderung
- National Institute for Research of Metabolic and Cardiovascular Diseases
Zitieren
APA
Sochorová, V., Kunštátová, V., Osmančík, P., Duška, F., Heřman, D., Waldauf, P., Povišer, L., Karch, J., Znojilová, L., Filipcová, V., Hozmanová, J., Veselá, J., & Hozman, M. (2025). COOPERATIVE-PFA: A Three-Arm Randomized Controlled Trial. Circulation, 152(3), 150-159. https://doi.org/10.1161/circulationaha.125.074427
Vancouver
Sochorová V, Kunštátová V, Osmančík P, Duška F, Heřman D, Waldauf P, et al. COOPERATIVE-PFA: A Three-Arm Randomized Controlled Trial. Circulation. 2025;152(3):150-159. doi:10.1161/circulationaha.125.074427
BibTeX
@article{Sochorov2025,
author = {Sochorová, Veronika and Kunštátová, Veronika and Osmančík, Pavel and Duška, František and Heřman, Dalibor and Waldauf, Petr and Povišer, Lukáš and Karch, Jakub and Znojilová, Lucie and Filipcová, Věra and Hozmanová, Jana and Veselá, Jana and Hozman, Marek},
title = {COOPERATIVE-PFA: A Three-Arm Randomized Controlled Trial},
journal = {Circulation},
year = {2025},
volume = {152},
number = {3},
pages = {150--159},
doi = {10.1161/circulationaha.125.074427}
}
EUVIMED